Managing AEs Associated With Bispecifics in RRMM
Closing out their discussion on relapsed/refractory multiple myeloma, experts consider adverse event management in patients receiving bispecifics followed by future directions in care.
Bispecific Antibodies in the Treatment of RRMM
Comprehensive perspectives on the role of bispecific antibodies in the treatment of relapsed/refractory multiple myeloma.
CAR-T Therapies Therapy in RRMM
A brief review of the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.
Patient Profile 3: A 57-Year-Old Woman With Triple-Class Refractory MM
Moving to the last patient profile, expert panelists discuss a patient with triple-class refractory multiple myeloma managed with BCMA-targeting bispecific therapy.
Treating Transplant-Ineligible NDMM With High-Risk Cytogenetics
Shared insight on the selection of therapy for patients with transplant-ineligible, newly diagnosed multiple myeloma and high-risk cytogenetics.
Selection and Duration of Therapy in Transplant-Ineligible NDMM
Expert panelists consider which regimen they would use, and for what duration, in the setting of transplant-ineligible, newly diagnosed multiple myeloma.
Patient Profile 2: A 72-Year-Old With Transplant-Ineligible NDMM
The panel moves on to review the profile of a patient with transplant-ineligible, newly diagnosed multiple myeloma managed with dara-Rd on the MAIA trial.
Duration of Therapy in NDMM
Before closing their discussion on transplant-eligible, newly diagnosed multiple myeloma, experts consider duration of therapy in this setting.
Selecting Appropriate Therapy for Transplant-Eligible NDMM
Panelists briefly review factors they use to select induction therapy for patients with transplant-eligible, newly diagnosed multiple myeloma.
Quadruplet Vs Triplet Induction Regimens for Transplant-Eligible NDMM
Shared insight on approved quadruplet vs triplet induction regimens for patients with transplant-eligible, newly diagnosed multiple myeloma, evaluated in the GRIFFIN, MASTER and GMMG-HD7 trials.
Patient Profile 1: A 62-Year-Old With Transplant-Eligible NDMM
Experts discuss a patient with transplant-eligible, newly diagnosed multiple myeloma managed with induction daratumumab-RVd and maintenance therapy.
2 Clarke Drive Cranbury, NJ 08512